Nathan Feather, an analyst from Morgan Stanley, maintained the Hold rating on WW International, Inc.. The associated price target remains the same with $38.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nathan Feather has given his Hold rating due to a combination of factors that balance potential upside with meaningful uncertainties. He views the upcoming peak season as a possible positive catalyst, noting that historically this period has driven substantial swings in subscriber growth and that early app and web-traffic trends are improving. At the current valuation, he believes the market is largely discounting upside from peak season, which creates an asymmetrical risk-reward skewed to the positive if execution improves. However, he does not assume strong outperformance as his central case, instead seeing the market as underestimating the probability—but not guaranteeing the realization—of better-than-expected results.
In addition, Feather highlights that the newly launched GLP-1 Success Program and Med+ offering expand WW’s addressable market, particularly among patients receiving weight-loss medication from primary care providers and in international regions without clinic-based services. He acknowledges that WW’s behavioral-coaching expertise and early consumer interest are encouraging, but he cautions that these initiatives are still nascent and unlikely to drive immediate, large-scale financial impact. Taken together, the combination of attractive optionality from new programs, improving seasonal dynamics, and a low multiple on forward EBITDA is offset by execution risk and the early-stage nature of new products, leading him to a balanced, Hold stance rather than a more decisive Buy or Sell.